Farhan Bangash, DO
Nephrology · Crystal Lake, ILNPI 1750549473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,186, more than ten times the $57 reported in 2019.
Across 171 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$708
- Amgen$496
- Bayer$484
- Travere Therapeutics, Inc.$368
- Otsuka America Pharmaceutical, Inc.$313
- Novartis$307
- plus $1K from 12 others
Across 121 payments — averaging $1305.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$145K
- AbbVie$13K
What the payments were for
- Food & beverage$3,83794%
- Education$2356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $708 |
| Amgen(2 entities) | 27 | $496 |
| Bayer | 20 | $484 |
| Travere Therapeutics, Inc. | 15 | $368 |
| Otsuka America Pharmaceutical, Inc. | 12 | $313 |
| Novartis | 11 | $307 |
| OPKO Pharmaceuticals, LLC | 12 | $245 |
| Vifor Pharma, Inc. | 10 | $231 |
| Boehringer Ingelheim | 11 | $210 |
| Calliditas Therapeutics US Inc. | 6 | $192 |
| Akebia Therapeutics Inc | 8 | $176 |
| Fresenius USA Marketing, Inc. | 4 | $88 |
| Ultragenyx Pharmaceutical Inc. | 3 | $63 |
| Daiichi Sankyo Inc. | 2 | $57 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Novo Nordisk | 2 | $37 |
| Ardelyx, Inc. | 1 | $35 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,072 in reported general payments places this provider in the 80th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 253 | $317,368 |
| VeltassaPatiromer Calcium Sorbitex | 39 | $58,309 |
| VelphoroSucroferric Oxyhydroxide | 15 | $41,541 |
| JardianceEmpagliflozin | 25 | $41,339 |
| LokelmaSodium Zirconium Cyclosilicate | 49 | $40,094 |
| Cinacalcet Hcl | 21 | $27,454 |
| EntrestoSacubitril/Valsartan | 18 | $25,782 |
| AuryxiaFerric Citrate | 11 | $21,486 |
| DapagliflozinDapagliflozin Propanediol | 15 | $19,270 |
| KerendiaFinerenone | 11 | $16,605 |
| Bumetanide | 218 | $7,560 |
| Sevelamer Carbonate | 52 | $4,889 |
| Potassium Chloride | 169 | $4,437 |
| Lanthanum Carbonate | 13 | $4,426 |
| Losartan Potassium | 428 | $3,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $708 | $357,463302 claims |
| Fresenius USA Marketing, Inc.Velphoro | $88 | $41,54115 claims |
| Boehringer IngelheimJardiance | $210 | $41,33925 claims |
| NovartisEntresto | $307 | $25,78218 claims |
| Akebia Therapeutics IncAuryxia | $176 | $21,48611 claims |
| BayerKerendia | $484 | $16,60511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 524 nephrology providers in Illinois.
Other nephrology in Crystal Lake
- Myles WolfChicago$2.1M
- Mohammed AhmedBolingbrook$1.1M
- Anis RaufHinsdale$453K
- Juan LermaEvergreen Park$351K
- Stuart SpragueEvanston$337K
- Suneel UdaniHinsdale$336K
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Omaima DeganiGurnee$184K
- Merry DownerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.